Cargando…
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
BACKGROUND: BI 2536, a novel Polo-like kinase 1 inhibitor, was assessed in patients with unresectable advanced exocrine adenocarcinoma of the pancreas. METHODS: The study employed a two-stage design. Randomised first-line patients received BI 2536 200 mg on day 1 (n=43) or 60 mg on days 1–3 (n=43) e...
Autores principales: | Mross, K, Dittrich, C, Aulitzky, W E, Strumberg, D, Schutte, J, Schmid, R M, Hollerbach, S, Merger, M, Munzert, G, Fleischer, F, Scheulen, M E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394983/ https://www.ncbi.nlm.nih.gov/pubmed/22699824 http://dx.doi.org/10.1038/bjc.2012.257 |
Ejemplares similares
-
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
por: Steinbild, S, et al.
Publicado: (2007) -
BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1
por: Gohda, Jin, et al.
Publicado: (2018) -
Cystic Neoplasms of the Exocrine
Pancreas
por: Mosimann, F., et al.
Publicado: (1990) -
Diabetes mellitus and the exocrine pancreas.
por: Gorelick, F. S.
Publicado: (1983) -
Malignant epithelial/exocrine tumors of the pancreas
por: Luchini, Claudio, et al.
Publicado: (2020)